Related Experiment Video
Updated: Aug 18, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Anagrelide-induced cardiomyopathy
1Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas 75246, USA.
Insights
Anagrelide, used for hematologic disorders, may cause serious heart problems like congestive heart failure. This case report highlights potential cardiovascular risks associated with anagrelide therapy.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Anagrelide is a medication used to treat hematologic disorders.
- Cardiovascular events have been reported with anagrelide use.
- The drug's mechanism may involve phosphodiesterase inhibition, leading to positive inotropic effects and vasodilation.
Observation:
- A 48-year-old woman with polycythemia vera experienced cardiotoxicity.
- Symptoms included congestive heart failure and palpitations.
- These events were suspected to be linked to anagrelide dosage adjustments.
Findings:
- The patient developed congestive heart failure and palpitations.
- Cardiotoxicity was temporally associated with anagrelide titration.
- This suggests a potential causal relationship between anagrelide and cardiovascular adverse events.
Implications:
- Clinicians should be aware of the potential cardiotoxicity of anagrelide.
- Monitoring for cardiovascular symptoms is crucial in patients treated with anagrelide.
- Further research is needed to fully understand and manage anagrelide-induced cardiotoxicity.
Abstract:
Anagrelide, a selective thrombocytopenic agent, is administered to treat a variety of hematologic disorders. Despite limited clinical experience with this drug, serious cardiovascular events, including congestive heart failure, have been reported. The proposed mechanism of cardiotoxicity is attributed to inhibition of phosphodiesterase, resulting in positive inotropic activity and vasodilation. A 48-year-old woman with polycythemia vera developed cardiotoxicity manifested by congestive heart failure and palpitations. It was suspected to be temporally related to titrating dosages of anagrelide.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

